Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/j.1468-3083.2011.04394.x ◽

2011 ◽

Vol 27 (1) ◽

pp. 125-128 ◽

Author(s):

S. Tyring ◽

J. Bagel ◽

C. Lynde ◽

P. Klekotka ◽

E.H.Z. Thompson ◽

...

Keyword(s):

Plaque Psoriasis ◽

Patient Reported Outcomes ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Patient Reported

Download Full-text

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.12081 ◽

2013 ◽

Vol 28 (2) ◽

pp. 192-203 ◽

Author(s):

C. Mamolo ◽

J. Harness ◽

H. Tan ◽

A. Menter

Keyword(s):

Patient Reported Outcomes ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Controlled Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Patient Reported

Download Full-text

A phase IV randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efalizumab in patients with moderate to severe plaque psoriasis involving the scalp

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2008.11.787 ◽

2009 ◽

Vol 60 (3) ◽

pp. AB181

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Download Full-text

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

British Journal of Dermatology ◽

10.1111/bjd.14493 ◽

2016 ◽

Vol 175 (2) ◽

pp. 273-286 ◽

Author(s):

K.A. Papp ◽

K. Reich ◽

C. Paul ◽

A. Blauvelt ◽

W. Baran ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Prospective Phase

Download Full-text

A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

British Journal of Dermatology ◽

10.1111/j.1365-2133.2012.11015.x ◽

2012 ◽

Vol 167 (3) ◽

pp. 649-657 ◽

Author(s):

A.B. Gottlieb ◽

R.G. Langley ◽

B.E. Strober ◽

K.A. Papp ◽

P. Klekotka ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2011.07.034 ◽

2012 ◽

Vol 67 (1) ◽

pp. 86-92 ◽

Author(s):

Jerry Bagel ◽

Charles Lynde ◽

Stephen Tyring ◽

Gregory Kricorian ◽

Yifei Shi ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study

The Journal of Dermatology ◽

10.1111/1346-8138.15733 ◽

2020 ◽

Author(s):

Seong Jun Seo ◽

Bong Seok Shin ◽

Joo‐Heung Lee ◽

Haeyoun Jeong

Keyword(s):

Plaque Psoriasis ◽

Korean Population ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS )

British Journal of Dermatology ◽

10.1111/bjd.19147 ◽

2020 ◽

Vol 183 (2) ◽

pp. 231-241 ◽

Author(s):

A.S. Paller ◽

M.M.B. Seyger ◽

G. Alejandro Magariños ◽

J. Bagel ◽

A. Pinter ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Paediatric Patients

Download Full-text

Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: Results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2015.02.939 ◽

2015 ◽

Vol 72 (5) ◽

pp. AB233 ◽

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Poster 156 Dysport®, AbobotulinumtoxinA, Improves Disease-Specific Quality of Life in Patients with Cervical Dystonia, as Measured by Patient-Reported Outcomes, in a Phase III, Randomized, Double-Blind, Placebo-Controlled Study

PM&R ◽

10.1016/j.pmrj.2014.08.550 ◽

2014 ◽

Vol 6 (9) ◽

pp. S239

Author(s):

Philippe Picaut ◽

Doctor of Pharmacy ◽

Werner Poewe ◽

Stanislav Vohanka ◽

Jan Ilkowski ◽

...

Keyword(s):

Quality Of Life ◽

Cervical Dystonia ◽

Patient Reported Outcomes ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Patient Reported ◽

Disease Specific

Download Full-text

Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17109 ◽

2021 ◽

Author(s):

D Thaçi ◽

AM Soliman ◽

K Eyerich ◽

A Pinter ◽

M Sebastian ◽

...

Keyword(s):

Clinical Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Therapy ◽

Patient Reported Outcomes ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Patient Reported ◽

Download Full-text